Targovax ASA: Announcement of fourth quarter and full year results 2018

Oslo, Norway, 4 February 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, will announce its fourth quarter and full year 2018 results on Thursday, 14 February 2019. A presentation by Targovax’s management to investors, analysts and the press will take place in Oslo at 10:00 CET.

The quarterly report and the presentation will be available at www.targovax.com in the Investors section from 07:30 CET.

Presentation
The presentation will take place at 10:00 CET at:

Hotel Continental
Stortingsgaten 24/26
0117 Oslo

The presentation will also be webcast live and can be accessed through www.targovax.com.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

Simon Conway/Stephanie Cuthbert – FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com